The Rise of Cochlear Gene Therapy DOI Creative Commons
Lukas D. Landegger, Ellen Reisinger, François Lallemend

и другие.

Molecular Therapy, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 1, 2024

Recent evidence provides strong support for the safe and effective use of gene therapy in humans with hearing loss. By means a single local injection set adeno-associated virus (AAV) vectors, was partially restored several children neurosensory nonsyndromic autosomal recessive deafness 9 (DFNB9), harboring variants OTOF gene. Current research focuses on refining endoscopic transmastoid procedures to reduce risks side effects, as emerging suggests bidirectional fluid exchanges between ear brain. Moreover, editing approaches novel AAV capsids are successfully tested animal models will likely lead enhanced targeting cochlea. Here, we cover recent advances cochlear therapy, provide an overview translational potential these new existing future clinical trials, highlight implications that remain be determined their application humans.Graphical abstract

Язык: Английский

The global prevalence of complete hearing loss in 204 countries and territories from 1992 to 2021: a systematic analysis for the global burden of disease study 2021 DOI Creative Commons
Guan‐Jiang Huang,

Zhi‐Jun Fan,

Biao-Qing Lu

и другие.

Frontiers in Public Health, Год журнала: 2025, Номер 13

Опубликована: Апрель 9, 2025

Background Complete hearing loss, especially the age-related type, poses a significant public health challenge globally. This study aims to assess global burden on prevalence of complete loss from 1992 2021 and forecast trends up 2036. Methods Using data Global Burden Disease (GBD) Study 2021, we assessed across 204 countries territories. We analyzed temporal in ASPR using Joinpoint regression, evaluated contributions age, period, cohort effects through Age-Period-Cohort modeling, performed decomposition analysis determine impact demographic epidemiological changes trends. Predictions future were made Bayesian (BAPC) Autoregressive Integrated Moving Average (ARIMA) models. Results By had reached 9.9 million cases, with declining 134.35 117.79 per 100,000. The overall Estimated Annual Percentage Change (EAPC) was−0.45. most reductions observed low-SDI regions, particularly Sub-Saharan Africa (EAPC: −0.74). In contrast, high-SDI including North America Western Europe, showed more modest declines −0.18). Notably, East Asia exhibited 62.3% increase prevalence, high-income Pacific showing highest relative rise at 83.97%. Age-related remained dominant cause, among individuals aged 60 above. Males affected than females. Population aging growth major drivers increased while population was primary factor areas. Conclusion remains high populations within despite ASPR. Significant regional disparities remain, highlighting need for targeted interventions improve access care affordable technologies regions.

Язык: Английский

Процитировано

0

Seventy-Five Years of Interactions: The Department of Physiology and Pharmacology at Karolinska Institutet andPharmacological Reviews DOI Open Access
Gunnar Schulte

Pharmacological Reviews, Год журнала: 2024, Номер 76(6), С. 972 - 977

Опубликована: Окт. 16, 2024

This special issue emerged from an informal discussion at editorial board meeting during 2023, where the 75th anniversaries of Pharmacological Reviews and Department Physiology Pharmacology Karolinska Institutet, Stockholm, Sweden were coincidentally discussed. The idea for

Язык: Английский

Процитировано

0

The Rise of Cochlear Gene Therapy DOI Creative Commons
Lukas D. Landegger, Ellen Reisinger, François Lallemend

и другие.

Molecular Therapy, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 1, 2024

Recent evidence provides strong support for the safe and effective use of gene therapy in humans with hearing loss. By means a single local injection set adeno-associated virus (AAV) vectors, was partially restored several children neurosensory nonsyndromic autosomal recessive deafness 9 (DFNB9), harboring variants OTOF gene. Current research focuses on refining endoscopic transmastoid procedures to reduce risks side effects, as emerging suggests bidirectional fluid exchanges between ear brain. Moreover, editing approaches novel AAV capsids are successfully tested animal models will likely lead enhanced targeting cochlea. Here, we cover recent advances cochlear therapy, provide an overview translational potential these new existing future clinical trials, highlight implications that remain be determined their application humans.Graphical abstract

Язык: Английский

Процитировано

0